Prevalence of Atopic Eczema Among Patients Seen in Primary Care: Data From The Health Improvement Network
Authors: Katrina Abuabara, Alexa Magyari, Charles E. McCulloch, Eleni Linos, David J. Margolis, Sinéad M. Langan
Journal: Annals of Internal Medicine (2018)

Letters5 March 2019Prevalence of Atopic Eczema Among Patients Seen in Primary Care: Data From The Health Improvement NetworkKatrina Abuabara, MD, MA, MSCE*, Alexa Magyari, BA*, Charles E. McCulloch, PhD, Eleni Linos, MD, PhD, David J. Margolis, MD, PhD, and Sinéad M. Langan, MSc, PhDKatrina Abuabara, MD, MA, MSCE*University of California, San Francisco, San Francisco, California (K.A., A.M., C.E.M., E.L.), Alexa Magyari, BA*University of California, San Francisco, San Francisco, California (K.A., A.M., C.E.M., E.L.), Charles E. McCulloch, PhDUniversity of California, San Francisco, San Francisco, California (K.A., A.M., C.E.M., E.L.), Eleni Linos, MD, PhDUniversity of California, San Francisco, San Francisco, California (K.A., A.M., C.E.M., E.L.), David J. Margolis, MD, PhDPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania (D.J.M.), and Sinéad M. Langan, MSc, PhDLondon School of Hygiene and Tropical Medicine, London, United Kingdom (S.M.L.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/M18-2246 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Atopic eczema (also known as atopic dermatitis, or simply eczema) was traditionally considered to remit in most children by adolescence. However, increasing genetic and epidemiologic evidence suggests that it is an episodic, inflammatory disorder that can occur throughout life (1). Atopic eczema affects between 10% and 25% of children in industrialized countries, but relatively little is known about physician-diagnosed adult disease (2).Objective: To estimate the age-specific prevalence of active atopic eczema across the lifespan in a large primary care population.Methods and Findings: We analyzed data between 1994 and 2013 from The Health Improvement Network. This U.K. cohort ...References1. Brunner PM, Silverberg JI, Guttman-Yassky E, Paller AS, Kabashima K, Amagai M, et al; Councilors of the International Eczema Council. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137:18-25. [PMID: 27771048] doi:10.1016/j.jid.2016.08.022 CrossrefMedlineGoogle Scholar2. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI; ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009;124:1251-8. [PMID: 20004783] doi:10.1016/j.jaci.2009.10.009 CrossrefMedlineGoogle Scholar3. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care. 2011;19:251-5. [PMID: 22828580] MedlineGoogle Scholar4. Abuabara K, Magyari AM, Hoffstad O, Jabbar-Lopez ZK, Smeeth L, Williams HC, et al. Development and validation of an algorithm to accurately identify atopic eczema patients in primary care electronic health records from the UK. J Invest Dermatol. 2017;137:1655-62. [PMID: 28428130] doi:10.1016/j.jid.2017.03.029 CrossrefMedlineGoogle Scholar5. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132:1132-8. [PMID: 24094544] doi:10.1016/j.jaci.2013.08.031 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of California, San Francisco, San Francisco, California (K.A., A.M., C.E.M., E.L.)Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania (D.J.M.)London School of Hygiene and Tropical Medicine, London, United Kingdom (S.M.L.)Financial Support: By grants from the Dermatology Foundation and the Robert Wood Johnson Foundation (Dr. Abuabara); grants KL2TR001870 (Drs. Abuabara and McCulloch) and K76AG054631, R21CA212201, and DP2CA225433 (Dr. Linos) from the National Institutes of Health; and a Wellcome Senior Clinical Fellowship in Science (205039/Z/16/Z; Dr. Langan).Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M18-2246.Reproducible Research Statement:Study protocol: Not available. Statistical code: Available from Dr. Abuabara (e-mail, katrina.[email protected]edu). Data set: Available for purchase at www.iqvia.com/locations/uk-and-ireland/thin.This article was published at Annals.org on 4 December 2018.* Dr. Abuabara and Ms. Magyari contributed equally to this work. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byEffect of acupuncture in eczema: An overview of systematic reviewsWhat do professional cleaners know about the skin care? A questionnaire‐based studyA combination of HLA-DP α and β chain polymorphisms paired with a SNP in the DPB1 3' UTR region, denoting expression levels, are associated with atopic dermatitisAtopic dermatitis across the life courseThe Multidimensional Burden of Atopic Dermatitis Among AdultsAdult atopic eczema and the risk of dementia: A population-based cohort studySeasonal Patterns and Trends in Dermatoses in PolandMicrobiologic characterisation of bacterial infections in children with atopic dermatitisAtopic dermatitis: filaggrin and skin barrier dysfunctionPrevalence of eczema among adults in the United States: a cross-sectional study in the All of Us research programPioneering global best practices in atopic dermatitis: results from the atopic dermatitis quality of care initiativeAge-dependent Distribution of Atopic Dermatitis in Primary Care: A Nationwide Population-based Study from FinlandPreliminary Clinical Experience with a Novel Optical–Ultrasound Imaging Device on Various Skin LesionsImpact of Althaea Officinalis extract in patients with atopic eczema: a double-blind randomized controlled trialThe epidemiology of atopic dermatitis in older adults: A population-based study in the United KingdomPatterns of Atopic Eczema Disease Activity From Birth Through Midlife in 2 British Birth CohortsThe Epidemiology and Global Burden of Atopic Dermatitis: A Narrative ReviewHuman leukocyte antigen class-I variation is associated with atopic dermatitis: A case-control studySafety of Systemic Medications Among Older Adults With Psoriasis and Atopic Dermatitis: A Systematic Review of Observational StudiesClinical and Economic Burden of Mild-to-Moderate Atopic Dermatitis in the UK: A Propensity-Score-Matched Case–Control StudyAtopic eczema in adulthood and mortality: UK population–based cohort study, 1998-2016The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017*Inclusion of Older Adults in Randomized Clinical Trials for Systemic Medications for Atopic DermatitisAssociation between fine mapping thymic stromal lymphopoietin and atopic dermatitis onset and persistenceAssociation of Filaggrin Loss-of-Function Variants With Race in Children With Atopic DermatitisWhich emollients are effective and acceptable for eczema in children? 5 March 2019Volume 170, Issue 5Page: 354-356KeywordsAllergic diseasesAtopic dermatitisChildrenDisclosureEczemaElderlyMolecular epidemiologyQuality of lifeScabiesSteroids ePublished: 4 December 2018 Issue Published: 5 March 2019 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...